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Abstract
The intake of the mainly plant-derived n-3 PUFA a-linolenic acid (ALA) has been reported to be associated with a lower risk of CHD. How-
ever, the results have been inconsistent. Therefore, the objective of the present study was to examine the association between the intake of
ALA and the risk of CHD. Potential effect modification by the intake of long-chain n-3 PUFA (n-3 LCPUFA) was also investigated. Data from
eight American and European prospective cohort studies including 148 675 women and 80 368 men were used. The outcome measure was
incident CHD (CHD event and death). During 4–10 years of follow-up, 4493 CHD events and 1751 CHD deaths occurred. Among men, an
inverse association (not significant) between the intake of ALA and the risk of CHD events and deaths was observed. For each additional
gram of ALA consumed, a 15 % lower risk of CHD events (hazard ratios (HR) 0·85, 95 % CI 0·72, 1·01) and a 23 % lower risk of CHD deaths
(HR 0·77, 95 % CI 0·58, 1·01) were observed. No consistent association was observed among women. No effect modification by the intake
of n-3 LCPUFA was observed.
Key words: a-Linolenic acid: CHD: Epidemiology
CHD is the leading cause of morbidity and mortality in the
world(1). CHD arises from genetic and modifiable lifestyle fac-
tors including diet. One of the important dietary components
identified is the low intake of n-3 PUFA. The marine product-
derived long-chain n-3 PUFA (n-3 LCPUFA), EPA and DHA,
have for long been the main focus of research with regard
to the importance of n-3 PUFA in relation to CHD. Since the
pioneering studies carried out among Greenland Eskimos
have suggested that high intakes of EPA and DHA can protect
against CHD(2), many studies and meta-analyses have con-
firmed this association(3–7). However, the long-term associ-
ation between the intake of the mainly plant-derived n-3
PUFA a-linolenic acid (ALA) and the risk of CHD is not
clear(8–11). A recent meta-analysis of three prospective studies
carried out in 2012 has suggested that each 1 g/d of ALA intake
is associated with a 20 % lower risk of CHD events(11).
*Corresponding author: M. S. Vedtofte, fax þ45 38 16 31 19, email mia.sadowa.vedtofte@regionh.dk
Abbreviations: ALA, a-linolenic acid; ARIC, Atherosclerosis Risk in Communities Study; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study;
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British Journal of Nutrition (2014), 112, 735–743 doi:10.1017/S000711451400138X

















The intake of fish and other marine products is limited in
many countries, and ALA primarily from plant oils and nuts
(e.g. rapeseed oils, walnuts and soyabean) is the predominant
source of n-3 PUFA in the typical Western diet. In the human
body, ALA is converted into n-3 LCPUFA by desaturation and
elongation, but this conversion is limited and generally much
lower in men than in women(12,13). The effect of ALA intake
on the risk of CHD may be influenced by n-3 LCPUFA,
because they, via feedback inhibition of the activity of D6-
desaturase (the key limiting enzyme), regulate the conversion
of ALA into n-3 LCPUFA. Therefore, it is possible that ALA may
particularly reduce the risk of CHD among individuals with a
low intake of n-3 LCPUFA(14).
In the present study, we investigated the association
between ALA intake and CHD risk in populations consuming
different diets and exhibiting a wide range of ALA intakes,
using data from eight American and European prospective
cohort studies included in the Pooling Project of Cohort
Studies on Diet and Coronary Disease. We hypothesised that
the intake of ALA was inversely associated with the risk of
CHD and that the inverse association between the intake of
ALA and the risk of CHD was stronger in subjects with a




A total of eleven prospective cohort studies (the Adventist
Health Study(15), the Atherosclerosis Risk in Communities
Study (ARIC)(16), the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study (ATBC)(17), the Finnish Mobile Clinic
Health Examination Survey (FMC)(18), the Glostrup Population
Study(19), the Health Professionals Follow-up Study (HPFS)(20),
the Israeli Ischemic Heart Disease Study (IIHD)(21), the Iowa
Women’s Health Study (IWHS)(22), the Nurses’ Health Study
(NHS)(23), the Va¨sterbotten Intervention Program (VIP)(24),
and the Women’s Health Study (WHS)(25)) met the following
criteria and were included in the Pooling Project of Cohort
Studies on Diet and Coronary Disease: (1) a published
prospective study with at least 150 incident CHD cases; (2) a
study determining usual dietary intake using a FFQ, a dietary
history interview, or a 7 d weighed food record at baseline; (3)
a validation or a repeatability study of the dietary intake
assessment method. Among these studies, three (the Adventist
Health Study, the Glostrup Population Study and the IIHD)
were excluded from the present analysis due to lack of infor-
mation on ALA intake. The characteristics of the remaining
eight studies, five carried out in the USA, two in Finland and
one in Sweden, are summarised in Table 1. From the cohorts,
we excluded individuals who were aged ,35 years, had a
history of CVD, diabetes, or cancer (except non-melanoma
skin cancer), and had an extreme energy intake, i.e. intakes
greater or less than three standard deviations from the
study-specific log-transformed mean energy intake of the
baseline populations. The final study population consisted
of 229 043 persons (65 % women).
Habitual dietary intake determination
Habitual dietary intake was determined at baseline using a FFQ
in seven of the cohort studies and by a dietary history interview
in one cohort study (Table 1). The FFQ that were used in the
ARIC, the NHS, the HPFS, the WHS and the IWHS were similar
or a modified version of the original sixty-one-item Willett FFQ
developed in 1980(23). However, as the FFQ were modified, the
number of items in each study differed; the FFQ used in the
ARIC, the HPFS, the WHS and the IWHS contained 66, 131,
131 and 116 items, respectively. As the ARIC used the oldest ver-
sion of the FFQ with only sixty-six items, it did not have the
same details on, for example, cooking oil. In the NHS carried
out in 1980, a sixty-one-item FFQ was used to assess dietary
intake. The questionnaire was expanded to 116 items in 1984
and administered in 1986 and 1990. The data from the NHS
used in the present study were those obtained in 1986. The par-
ticipants were asked to report how often, on average, they had
consumed given amounts of the various specified foods during
the previous year. The average daily intake of nutrients was
then computed by multiplying the frequency of intake by the
nutrient composition of the specified portion size. The compo-
sition values of ALA (and other nutrients) were obtained from
the Harvard University food composition database and the US
Department of Agriculture(26). The Finnish FFQ used in the
ATBC included 276 food items, and the participants were
asked to report their usual intake and portion size of foods
during the previous year(17,27). The type of fat used on bread,
which is an important source of fat in the Finnish diet, was
specified by the brand name of the product(28). The fatty acid
content of the foods was based on analyses of seventy-seven
fatty acids present in Finnish foods carried out at the Depart-
ment of Food Chemistry, University of Helsinki(28). The ques-
tionnaire used in the VIP(24) included eighty-four food items.
The subjects were asked to report their habitual dietary intake
during the previous year and typical portion sizes were indi-
cated using colour photographs. The average daily intake was
calculated by multiplying the frequency of intake by a portion
size value using the Swedish national food composition data-
base(24). The FMC used a dietary history interview, where the
interviewer asked the participants about their habitual dietary
intake during the previous year(29). The subjects reported
their food intake on a daily, weekly or monthly basis. The ingre-
dients of mixed foods were broken down into components
using a recipe file and the intake of fruits and berries, veg-
etables, and cereals as well as the subgroups of these food
categories and separate food items such as dairy and meat
products was calculated per d. The total energy intake was
calculated from the intake of protein, fat and available carbo-
hydrates according to the Finnish food composition tables(29).
Outcome
The outcome of interest was incident CHD events (fatal and
non-fatal). Because only the IWHS had self-reported data on
incident CHD, we only used data on fatal CHD events from
this study. All studies used standardised criteria to define
non-fatal and fatal CHD cases(30).

















Table 1. Characteristics of the cohort studies included in the Pooling Project of Cohort Studies on Diet and Coronary Disease
(Median values and 80 % central ranges)




































ARIC USA 1987 6481 53 47–62 9·2 – 123 – FFQ 0·70 0·54–0·90 0·21 0·05–0·62
FMC Finland 1966 2481 49 38–65 10·0 10·0 162 48 DH 0·53 0·42–0·87 0·15 0·06–0·36
IWHS USA 1986 30 180 61 56–67 – 10·0 – 294 FFQ 0·94 0·71–1·25 0·13 0·02–0·35
NHS USA 1986 61 706 52 43–62 10·0 10·0 696 208 FFQ 0·97 0·72–1·33 0·18 0·06–0·42
VIP Sweden 1992 10 555 50 40–60 4·1 – 23 – FFQ 1·26 0·96–1·81 0·10 0·03–0·23
WHS USA 1993 37 272 52 46–64 5·3 5·3 152 10 FFQ 0·92 0·69–1·26 0·15 0·05–0·36
Men
ARIC USA 1987 5240 54 47–63 9·2 9·2 269 51 FFQ 0·93 0·72–1·20 0·20 0·03–0·62
ATBC Finland 1985 21 141 57 51–65 6·0 6·1 1339 534 FFQ 1·20 0·74–1·92 0·34 0·16–0·66
FMC Finland 1966 2712 47 37–63 10·0 10·0 322 147 DH 0·68 0·55–0·98 0·23 0·09–0·59
HPFS USA 1986 41 754 53 42–67 9·7 9·7 1273 421 FFQ 1·12 0·83–1·54 0·26 0·07–0·58
VIP Sweden 1992 9521 50 40–60 4·1 4·1 134 38 FFQ 1·73 1·27–2·51 0·12 0·03–0·30
Women, total 148 675 1156 560 1·01 0·58–1·64 0·15 0·04–0·42
Men, total 80 368 3337 1191 1·17 0·64–1·62 0·26 0·06–0·66
Total 229 043 4493 1751 1·06 0·60–1·06 0·19 0·05–0·50
ALA, a-linolenic acid; ARIC, Atherosclerosis Risk in Communities Study; FMC, Finnish Mobile Clinic Health Examination Survey; DH, dietary history interview; IWHS, Iowa Women’s Health Study; NHS, Nurses’ Health Study;
VIP, Va¨sterbotten Intervention Program; WHS, Women’s Health Study; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; HPFS, Health Professionals Follow-up Study.
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Statistical analyses
Within each study, hazard ratios (HR) with 95 % CI for the inci-
dence of fatal and non-fatal CHD events were calculated using
Cox proportional hazards regression with follow-up duration
in the study (years) as the time metric(31). The observation
time for each participant was defined as the date on which
information on dietary intake was obtained and until the
occurrence of CHD, death from another cause, disappearance
or end of the follow-up, whichever came first. Studies with
follow-up periods of more than 10 years were truncated to
reduce possible effect modification by time. The analyses
were carried out separately for men and women. The intake
of ALA was adjusted for total energy using the residual
method and modelled as a continuous variable followed by
analyses with ALA intake as a categorical variable, in quintiles,
and also as a binary variable (below/above the median).
Subsequently, to assess possible effect modification by the
intake of n-3 LCPUFA, we stratified analyses with ALA and
n-3 LCPUFA intakes using combined categories of higher
(.median) v. lower (,median) intake. Furthermore, analyses
were carried out to explore possible age-related differences in
the association between ALA intake and CHD risk. The study
population was divided into two age groups in further ana-
lyses: those aged ,60 years at baseline and those aged $60
years at baseline. The study-specific logs of HR were weighted
by the inverse of their variances, and a pooled (combined)
estimate of the HR was computed using a random-effects
model. Evidence for between-study heterogeneity among the
study-specific HR was examined using the estimated
between-study variance component Q statistic(31).
The following potential confounders were included in the
statistical models: BMI (,23, 23–25, 25–30, or .30 kg/m2);
highest attained educational level (,high school, high
school, or .high school); smoking habits (non-, ex-, and
current-smokers and in the last category 1–4, 5–14, 15–24,
or $25 cigarettes/d); physical activity (five levels); alcohol
intake (0, 0 to ,5, 5 to ,10, 10 to ,15, 15 to ,30, 30 to
,50, or .50 g/d); total energy intake (the sum of intakes of
energy derived from fat, carbohydrates and protein in kJ/d);
SFA, trans-fatty acid, MUFA, linoleic acid (LA), and n-3
LCPUFA intake in g/d; quintiles of dietary fibre intake; history
of hypertension (yes or no). The association between the
intake of ALA and the risk of CHD was investigated using
three models. Model 1 included energy-adjusted intake of
ALA in g/d and age at baseline (years), as well as the calendar
year in which the baseline diet questionnaire was returned.
The variables were entered into the model through the
STRATA statement. Model 2 included the variables of model
1 and the following known risk factors for CHD: BMI; edu-
cational level; smoking habits; physical activity; history of
hypertension. Model 3 included the variables of model 2
and the following dietary risk factors: alcohol intake; total
energy intake; quintiles of fibre intake; trans-fatty acid, SFA,
MUFA, LA, and n-3 LCPUFA intake. We tested ALA intake for
nonlinearity by including an energy-adjusted ALA variable
squared to the model and pooled the effect estimate for this
term. The analyses were carried out using SAS 9.2 statistical
software (SAS Institute, Inc.).
Results
The characteristics of the cohort studies are given in Table 1.
During 4–10 years of follow-up, 4493 CHD events and 1751
CHD deaths occurred among the 229 043 subjects. The 10th,
50th and 90th percentiles of energy-adjusted intake of ALA
were 0·58, 1·01 and 1·64 g/d in women, respectively, and
0·64, 1·17 and 1·62 g/d in men, respectively. The intake of
ALA was modestly correlated with the intake of LA (Pearson’s
correlation ¼ 0·42, P,0·0001), but there was no correlation
between the intake of ALA and that of n-3 LCPUFA (Pearson’s
correlation ¼ 20·005, P¼0·007).
Combined HR and 95 % CI for CHD events and deaths for
an increase of 1 g/d in the intake of ALA are given in Table 2.
There was a tendency towards a significant effect modification
by sex for ALA v. CHD death (P for interaction¼0·07). Among
men, a non-significant inverse association was observed
between the intake of ALA and the risk of CHD events and
deaths. For each additional gram of ALA consumed, a 15 %
Table 2. Combined risk of CHD events and deaths for an additional intake of 1 g/d of a-linolenic acid (ALA)
(Hazard ratios (HR) and 95 % confidence intervals)*




HR 95 % CI HR 95 % CI HR 95 % CI
ALA, CHD events
Model 1† 0·94 0·82, 1·08 0·95 1·07 0·66, 1·74 0·95 0·86, 1·05
Model 2‡ 0·93 0·84, 1·04 0·88 0·96 0·67, 1·39 0·95 0·86, 1·05
Model 3§ 0·88 0·75, 1·02 0·42 1·02 0·65, 1·59 0·85 0·72, 1·01
ALA, CHD deaths
Model 1† 0·95 0·82, 1·09 0·62 1·04 0·64, 1·68 0·93 0·80, 1·09
Model 2‡ 0·96 0·83, 1·11 0·97 0·96 0·64, 1·45 0·96 0·82, 1·13
Model 3§ 0·88 0·68, 1·14 0·07 1·23 0·80, 1·89 0·77 0·58, 1·01
* Data were analysed using Cox proportional hazards regression.
† Model 1 included energy-adjusted intake of ALA expressed in g/d. Age at baseline (years) and the calendar year in which the baseline question-
naire was returned were entered into the model through the STRATA statement.
‡ Model 2 included the variables of model 1 and the following known risk factors for CHD: smoking habits; BMI; physical activity; educational level;
history of hypertension.
§ Model 3 included the variables of model 2 and the following dietary risk factors: alcohol intake; total energy intake (where alcohol is excluded);
fibre intake; MUFA, SFA, trans-fatty acid, long-chain n-3 fatty acid, and linoleic acid intake.

















lower risk of CHD events (HR 0·85, 95 % CI 0·72, 1·01) and a
23 % lower risk of CHD deaths (HR 0·77, 95 % CI 0·58, 1·01)
were observed. Among women, no consistent association
was observed between the intake of ALA and the risk of
CHD events (HR 1·02, 95 % CI 0·65, 1·59) or CHD deaths
(HR 1·23, 95 % CI 0·80, 1·89). Because the ARIC used the
FFQ with only sixty-six items, we carried out an additional
analysis without including the ARIC; however, this did not
alter the findings (data not shown). The study-specific and
combined HR and 95 % CI for CHD events and deaths for an
increase of 1 g/d in the intake of ALA are shown in Figs. 1
and 2. The test for the presence of heterogeneity among the
individual studies did not indicate any significant differences
(P for heterogeneity among the studies were 0·33 and 0·72
for CHD events and deaths, respectively, among women and
0·37 and 0·39 for CHD events and deaths, respectively,
among men). In analyses with ALA intake in quintiles, the
lowest risk of CHD events was observed among those in the
fifth quintile than in those in the first quintile among both
women and men, but the differences were not significant
(data shown in online supplementary Fig. S1). Among men,
the lowest risk of CHD deaths was also observed in those in
the fifth quintile than in those in the first quintile, but the
differences were not significant (data shown in online sup-
plementary Fig. S1). When the intake of ALA was evaluated
as higher (.median) v. lower (,median) among men, a
significantly lower risk of CHD events was observed among
men with an ALA intake value above the median (1·17 g/d)
than in those with an intake value below the median (HR
0·91, 95 % CI 0·83, 1·00). No significant differences
were observed among women when the intake of ALA was
evaluated as higher (.median) v. lower (,median) or
among men when the outcome was CHD deaths (data given
in Table S1, available online).
When assessing whether the association between ALA
intake and CHD risk was modified by n-3 LCPUFA, the
intake of ALA was found to be most strongly associated with















0·5 1 5 10 25
Women, CHD event Men, CHD event
Fig. 1. Study-specific and combined risk of CHD events for each additional g/d intake of a-linolenic acid in (A) women and (B) men in the Pooling Project of Cohort
Studies on Diet and Coronary Disease. The multivariate model was adjusted for age at baseline and the calendar year in which the baseline questionnaire was
returned, smoking habits, BMI, physical activity, educational level, history of hypertension, alcohol intake, total energy intake, fibre intake, and MUFA, trans-fatty
acid, SFA, linoleic acid, and long-chain n-3 PUFA intake. Within each study, hazard ratios (HR) with 95 % CI for the incidence of a CHD event and CHD death
were calculated using Cox proportional hazards regression. Values are study-specific HR (V), with 95 % CI represented by horizontal lines. The area of the
V reflects the study-specific weight. The ‘total V’ represents the pooled HR and 95 % CI. (A) P for heterogeneity¼0·33; combined HR 1·02, 95 % CI 0·65, 1·59;
(B) P for heterogeneity¼0·37; combined HR 0·85, 95 % CI 0·72, 1·01. ARIC, Atherosclerosis Risk in Communities Study; ATBC, Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study; FMC, Finnish Mobile Clinic Health Examination Survey; HPFS, Health Professionals Follow-up Study; WHS, Women’s Health Study;
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Men, CHD deathWomen, CHD death
Fig. 2. Study-specific and combined risk of CHD death for each additional g/d intake of a-linolenic acid in (A) women and (B) men in the Pooling Project of Cohort
Studies on Diet and Coronary Disease. The multivariate model was adjusted for age at baseline and the calendar year in which the baseline questionnaire was
returned, smoking habits, BMI, physical activity, educational level, history of hypertension, alcohol intake, total energy intake, fibre intake, and MUFA, trans-fatty
acid, SFA, linoleic acid, and long-chain n-3 PUFA intake. Within each study, hazard ratios (HR) with 95 % CI for the incidence of a CHD event and CHD death
were calculated using Cox proportional hazards regression. Values are study-specific HR (V), with 95 % CI represented by horizontal lines. The area of the
V reflects the study-specific weight. The ‘total V’ represents the pooled HR and 95 % CI. (A) P for heterogeneity¼0·72; combined HR 1·23, 95 % CI 0·80, 1·89;
(B) P for heterogeneity¼0·39; combined HR 0·77, 95 % CI 0·58, 1·01. ARIC, Atherosclerosis Risk in Communities Study; ATBC, Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study; FMC, Finnish Mobile Clinic Health Examination Survey; HPFS, Health Professionals Follow-up Study; IWHS, Iowa Women’s Health
Study; NHS, Nurses’ Health Study; VIP, Va¨sterbotten Intervention Program; WHS, Women’s Health Study.

















of the analyses revealed a significant association and no effect
modification was observed. Carrying out analyses the same as
those used to obtain data shown in Fig. 3, but with the cut-off
values of n-3 LCPUFA of 0·1 g, suggested by Mozaffarian
et al.(14), was not possible, due to the limited number of
cases in the lowest-intake group. In interaction analysis with
a common reference (low ALA intake and low n-3 LCPUFA
intake), the lowest risk of CHD events was observed among
women with a high intake of ALA intake and a low intake
of n-3 LCPUFA (HR 0·83, 95 % CI 0·68, 1·02; P for
trend¼0·06) than among those with a low intake of both
types of n-3 PUFA (Table S2, available online). Among men,
the lowest risk of CHD was observed when both ALA and
n-3 LCPUFA intakes were high. In age-stratified analyses, the
intake of ALA was not significantly associated with the risk
of CHD and no effect modification by age was observed
(data not shown).
Discussion
In the present study, we found a non-significant inverse
association between the dietary intake of ALA and the risk
of incident CHD events and CHD deaths among men. The
pooling of data from eight large cohort studies is a major
strength of the present study and allowed studying the associ-
ation between the intake of ALA and the risk of CHD among
women and men in different populations consuming different
diets and exhibiting a wide range of intakes. Variations in
intake are essential for detecting potential associations with
health. Furthermore, an advantage of using a pooling study
design rather than a meta-analysis is that this design greatly
reduces the risk of publication bias, because results originated
both from studies that did not previously publish on the
association between ALA intake and CHD risk and from
studies that did. Indeed, only three of the eight studies
included (NHS(26,32), ATBC(28) and HPFS(14,33)) had reported
results from such an analysis earlier. Another strength of this
pooled study is that data on the intake of ALA as well as
covariates were harmonised and the same statistical approach
was used across all the studies. Habitual dietary intake was
determined using validated FFQ or by dietary history inter-
views. ALA levels in human tissue may provide a more accu-
rate measure of habitual ALA intake than dietary records or
questionnaires. However, ALA status in tissues may be influ-
enced by metabolic differences between subjects with regard
to genetics, sex and background diet, and day-to-day vari-
ations in tissue levels cannot be excluded either. The fact
that our particular pooling study of prospective cohorts
required an assumption of no changes in diet over time may
also contribute to measurement error over time. Repeated
measurements are required to reduce this, but these were
available only for a small selected subset. Furthermore, the
PUFA composition of foods, e.g. butter, have changed over
time, meaning that even though people have used the same
type and amount of butter during their lifetime, their fatty
acid intakes have changed. This change is partly explained
by the change in the practice of feeding ruminants with
concentrated cereal grain-based feed rather than with grass,
which is naturally rich in ALA. At the inception of the NHS
and the HPFS in 1986, approximately 15–20 % of ALA was
derived from beef and dairy sources, but this percentage
waned with follow-up.
Fatty acid compositions vary a lot in ready-made dishes and
take-away foods, as well as in biscuits and cakes (depending
on whether the fat used is of animal or plant origin). Further-
more, ALA (and fat in general) is difficult to be recognised and
quantified in questionnaires and interviews, due to its role in
food preparation – frying and cooking as well as a component
in sauces and dressings. This could lead to random misclassi-
fication of ALA intake, which may result in the attenuation of
associations. In the USA, e.g. in the NHS and the HPFS, the pri-
mary source of ALA is mayonnaise or other creamy dressings
or oil and vinegar salad dressing, which may be difficult to be
quantified using FFQ. Because salad dressings are major
sources of ALA, ALA may be a proxy for vegetable intake;
therefore, it could have been interesting to carry out stratified
analyses on the intake of vegetables/salad in an attempt to
remove confounding by the intake of vegetables/salad. We
did not make any adjustment for vegetable/salad intake,












































Fig. 3. Risk of (A) CHD events and (B) CHD deaths associated with each 1 g/d of a-linolenic acid (ALA) intake, among men and women with below (X) or above
(f) median n-3 long-chain PUFA intake (women: 0·15 g/d; men: 0·26 g/d). Values are hazard ratios (HR), with 95 % CI represented by vertical bars. Data were
analysed using Cox proportional hazards regression. The model was adjusted for age at baseline and the calendar year in which the baseline questionnaire was
returned, smoking habits, BMI, physical activity, educational level, history of hypertension, alcohol intake, total energy intake, fibre intake, MUFA, trans-fatty acid,
SFA, and linoleic acid intake. No significant differences were observed in women ((A) P¼0·42 and (B) P¼0·43) and men ((A) P¼0·92 and (B) P¼0·79).

















included in the Pooling Project of Cohort Studies on Diet and
Coronary Disease, and one principle of pooling is to treat all
cohorts the same (same confounders). However, a previous
study using data from only the NHS has made further adjust-
ment for vegetable intake without any change in the
results(26). However, the association could still have been
influenced by a generally healthier lifestyle and diet of those
who consumed more vegetables or salad. Another challenge
in evaluating the association between ALA intake and CHD
risk is that the intakes of LA and ALA are difficult to be differ-
entiated, as they are often present in the same product, e.g.
soyabean oil, margarine and mayonnaise. However, in the
present study, the correlation coefficient was only 0·42, thus
enabling statistical adjustment of LA intake in the multivariate
analyses.
Several prospective cohort studies have evaluated the
association between ALA intake and CHD risk and obtained
inconsistent results(14,26,28,32–34). Indeed, our findings are in
line with those of a recent meta-analysis of thirteen prospec-
tive studies carried out in 2012 showing that higher ALA
intakes (each 1 g/d increment) are associated with a 10 %
lower risk of incident CVD (HR 0·90, 95 % CI 0·81, 0·99)(11).
However, in the evaluation of the association between the
intake of ALA and the risk of CVD subtypes, CHD events
and CHD deaths, only three studies were included in the
meta-analysis of CHD events and six studies in the analysis
of CHD deaths and the association was found to be significant
only for ALA intake and CHD deaths (HR 0·80, 95 % CI 0·65,
0·98) (ALA and CHD events: HR 0·84, 95 % CI 0·61, 1·15). Of
these nine studies, four used cohorts that were also included
in the present study (NHS, HPFS and ATBC). Only two of
the nine studies were conducted in women (data from the
NHS)(26,32) and six were conducted solely in men(28,33,35–38),
whereas the last study was conducted in a sample of both
the sexes, with 27 % women and 73 % men(39). In the present
study, we obtained different results for women and men.
Whether the different results obtained for women and men
reflect true biological differences or are due to power or are
caused by some kind of bias remains to be determined. On
the other hand, an inverse association between ALA intake
and CHD risk is theoretically more likely among women
than among men, as several studies have shown that the con-
version of ALA into n-3 LCPUFA is stimulated by oestrogen
and is greater in women(12,13). The association between ALA
intake and CHD risk has been evaluated by two prior studies
in women, with both being carried out using data from the
NHS(26,32) and included in the recent meta-analysis by Pan
et al.(11). In one of these studies, Hu et al.(26) found that the
intake of ALA is associated with a lower risk of CHD deaths
(after 10 years of follow-up). In the other study, carried out
by Albert et al.(32), analyses were carried out for both
sudden death and overall CHD death and no association
was found between the intake of ALA and the risk of total
CHD deaths (after 18 years of follow-up). Albert et al.(32) con-
cluded that the beneficial effects of ALA intake on CHD deaths
found by Hu et al.(26) were probably due to its beneficial
effects on sudden deaths, which account for a higher pro-
portion of CHD deaths in younger women. Both these studies
carried out using data from the NHS used a simple updated
analysis that used the most recent ALA value available,
which may explain the deviation of the results of the NHS in
the present study. Furthermore, the age distribution in the
present study was similar for both men and women, but
the number of female cases was lower (death ¼ 560 and
event ¼ 1156) than that of male cases (death ¼ 1191 and
event ¼ 3337), because women, in general, are older
when they experience CHD. Therefore, the estimate of an
association between ALA intake and CHD risk among
women may be statistically unclear, which may also explain
the different results.
Mozaffarian et al.(14) showed that each additional 1 g/d
intake of ALA is associated with a 58 % lower risk of CHD
events (HR 0·42, 95 % CI 0·23, 0·75) among men with low
n-3 LCPUFA intakes (,0·1 g/d) and is not associated with
the risk of CHD events among men with higher n-3 LCPUFA
intakes (.0·1 g/d) (P for interaction¼0·0006). In the present
study, among men with n-3 LCPUFA intakes below the
median (,0·26 g/d), each 1 g/d of ALA intake was associated
with a 27 % lower risk of CHD events (HR 0·73, 95 % CI 0·51,
1·04), but among men with n-3 LCPUFA intakes above the
median, no significant association was observed (HR 0·90,
95 % CI 0·72, 1·12) (P for interaction¼0·92). Furthermore, no
effect modification by the intake of n-3 LCPUFA was observed
among women. Albert et al.(32) have reported an additive
effect of ALA and n-3 LCPUFA, indicating that the lowest
risk of sudden cardiac deaths occurred among those with
the highest intakes of both ALA and n-3 LCPUFA. In the pre-
sent study, the lowest risk of CHD events and deaths was
observed among men with high intakes of both ALA and
n-3 LCPUFA, although it was not significant. However, the
lowest risk of CHD events was observed among women
with low ALA intakes and high n-3 LCPUFA intakes (HR
0·83, 95 % CI 0·68, 1·02; P for trend¼0·06) than among
women with low intakes of both types of n-3 PUFA. Although
CHD deaths and CHD events are both atherosclerotic dis-
orders and have common risk factors, we found signs of
differential effect modification by the ingestion of n-3
LCPUFA for the association between ALA intake and risk
depending on whether the outcome was a CHD event or
CHD death. However, ALA may be more important in individ-
uals with low n-3 LCPUFA intakes because these individuals
need ALA, whereas individuals with high n-3 LCPUFA intakes
do not need it to achieve optimal levels of n-3 LCPUFA – so it
may not be so much the feedback inhibition, but the
deficiency of n-3 LCPUFA itself that matters. In our previous
study in Danish men and women(40), we found no effect
modification by the ingestion of n-3 LCPUFA for the associ-
ation between ALA intake and CHD risk.
Conclusion
In this large pooled study on the association between dietary
ALA intake and CHD risk, an inverse association was observed
among men; however, it was not significant. No consistent
association was observed among women. This is the largest
and most powerful study to evaluate the association between

















ALA intake and CHD risk to date. Given that a higher intake of
ALA was found to reduce the risk of CHD, although only
among men, from a public health point of view, it may be
feasible to increase ALA intake. Rapeseed oil (which is rich
in ALA) is the cheapest oil in many countries and thus can
be used in household cooking by a majority of populations.
However, rapeseed oil is best for raw use (i.e. salad dressing)
and not for heating due to its degree of unsaturation. Other
sources of ALA are, for instance, walnuts and flaxseeds,
although their use is not very common in all populations.
To obtain 1 g of ALA, one has to consume two teaspoons of
rapeseed oil or 15 g of walnuts or 6 g of flaxseeds. Sex differ-
ences in prospective cohort studies have received little atten-
tion and deserve further investigation.
Supplementary material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/S000711451400138X
Acknowledgements
The authors are grateful to Alberto Ascherio and Aaron
Folsom for their comments on the manuscript and involve-
ment in the Pooling Project of Cohort Studies on Diet and
Coronary Disease. They are also thankful to Gearo´id
O’Reilly for statistical assistance. They thank the staff and
participants of the ARIC, the ATBC, the FMC, the HPFS, the
IWHS, the NHS, the VIP and the WHS for their important
contributions.
This work was carried out as a part of the research pro-
gramme of the Danish Obesity Research Centre (DanORC).
DanORC is supported by the Danish Council for Strategic
Research (grant no. 2101-06-0005) and the National Institute
of Health grants P01 CA87969 (NHS), UM1 CA167552 (HPFS)
and R01 HL58904.
The authors’ contributions are as follows: M. S. V., M. U. J.,
L. L. and B. L. H. contributed to the study concept and design;
M. S. V., M. U. J., L. L., B. L. H., G. H., G. C., J. B., P. K., J. V.,
L. M. S., K. R., E. B. R. and E. J. O. interpreted the data and
critically revised the manuscript; M. S. V. drafted the manu-
script; M. S. V. and E. J. O. carried out the statistical analyses.
None of the authors has any conflicts of interest to declare.
References
1. WHO (2011) World Heart Federation, World Stroke Organiz-
ation. Global Atlas on Cardiovascular Disease Prevention
and Control. Geneva: WHO.
2. Bang HO, Dyerberg J & Hjoorne N (1976) The composition
of food consumed by Greenland Eskimos. Acta Med Scand
200, 69–73.
3. Hansen SN & Harris WS (2007) New evidence for the cardio-
vascular benefits of long chain omega-3 fatty acids. Curr
Atheroscler Rep 9, 434–440.
4. Harris WS, Miller M, Tighe AP, et al. (2008) Omega-3
fatty acids and coronary heart disease risk: clinical and
mechanistic perspectives. Atherosclerosis 197, 12–24.
5. Harris WS, Kris-Etherton PM & Harris KA (2008) Intakes of
long-chain omega-3 fatty acid associated with reduced risk
for death from coronary heart disease in healthy adults.
Curr Atheroscler Rep 10, 503–509.
6. Mozaffarian D & Wu JH (2011) Omega-3 fatty acids and
cardiovascular disease: effects on risk factors, molecular
pathways, and clinical events. J Am Coll Cardiol 58,
2047–2067.
7. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, et al.
(2012) Long chain omega-3 fatty acids and cardiovascular
disease: a systematic review. Br J Nutr 107, Suppl. 2,
S201–S213.
8. Brouwer IA, Katan MB & Zock PL (2004) Dietary a-linolenic
acid is associated with reduced risk of fatal coronary heart
disease, but increased prostate cancer risk: a meta-analysis.
J Nutr 134, 919–922.
9. Wang C, Harris WS, Chung M, et al. (2006) n-3 Fatty acids
from fish or fish-oil supplements, but not a-linolenic
acid, benefit cardiovascular disease outcomes in primary-
and secondary-prevention studies: a systematic review.
Am J Clin Nutr 84, 5–17.
10. Geleijnse JM, de Goede J & Brouwer IA (2010) a-Linolenic
acid: is it essential to cardiovascular health? Curr Atheroscler
Rep 12, 359–367.
11. Pan A, Chen M, Chowdhury R, et al. (2012) a-Linolenic acid
and risk of cardiovascular disease: a systematic review and
meta-analysis. Am J Clin Nutr 96, 1262–1273.
12. Burdge G (2004) a-Linolenic acid metabolism in men and
women: nutritional and biological implications. Curr Opin
Clin Nutr Metab Care 7, 137–144.
13. Decsi T & Kennedy K (2011) Sex-specific differences in
essential fatty acid metabolism. Am J Clin Nutr 94, Suppl.
6, 1914S–1919S.
14. Mozaffarian D, Ascherio A, Hu FB, et al. (2005) Interplay
between different polyunsaturated fatty acids and risk of
coronary heart disease in men. Circulation 111, 157–164.
15. Fraser GE, Strahan TM, Sabate J, et al. (1992) Effects of
traditional coronary risk factors on rates of incident coronary
events in a low-risk population. The Adventist Health Study.
Circulation 86, 406–413.
16. The ARIC Investigators (1989) The Atherosclerosis Risk in
Communities (ARIC) Study: design and objectives. The
ARIC investigators. Am J Epidemiol 129, 687–702.
17. The ATBC Cancer Prevention Study Group (1994) The
alpha-tocopherol, beta-carotene lung cancer prevention
study: design, methods, participant characteristics, and
compliance. The ATBC Cancer Prevention Study Group.
Ann Epidemiol 4, 1–10.
18. Knekt P, Reunanen A, Jarvinen R, et al. (1994) Antioxidant
vitamin intake and coronary mortality in a longitudinal
population study. Am J Epidemiol 139, 1180–1189.
19. Schroll M, Jorgensen T & Ingerslev J (1992) The Glostrup
Population Studies, 1964–1992. Dan Med Bull 39, 204–207.
20. Rimm EB, Giovannucci EL, Stampfer MJ, et al. (1992) Repro-
ducibility and validity of an expanded self-administered
semiquantitative food frequency questionnaire among male
health professionals. Am J Epidemiol 135, 1114–1126.
21. Goldbourt U & Yaari S (1990) Cholesterol and coronary heart
disease mortality. A 23-year follow-up study of 9902 men in
Israel. Arteriosclerosis 10, 512–519.
22. Folsom AR, Kushi LH, Anderson KE, et al. (2000) Associ-
ations of general and abdominal obesity with multiple
health outcomes in older women: the Iowa Women’s
Health Study. Arch Intern Med 160, 2117–2128.

















23. Willett WC, Sampson L, Stampfer MJ, et al. (1985) Reprodu-
cibility and validity of a semiquantitative food frequency
questionnaire. Am J Epidemiol 122, 51–65.
24. Winkvist A, Hornell A, Hallmans G, et al. (2009) More
distinct food intake patterns among women than men in
northern Sweden: a population-based survey. Nutr J 8, 12.
25. Lee IM, Cook NR, Gaziano JM, et al. (2005) Vitamin E in the
primary prevention of cardiovascular disease and cancer: the
Women’s Health Study: a randomized controlled trial. JAMA
294, 56–65.
26. Hu FB, Stampfer MJ, Manson JE, et al. (1999) Dietary intake
of a-linolenic acid and risk of fatal ischemic heart disease
among women. Am J Clin Nutr 69, 890–897.
27. Pietinen P, Hartman AM, Haapa E, et al. (1988) Reproducibil-
ity and validity of dietary assessment instruments. I. A
self-administered food use questionnaire with a portion
size picture booklet. Am J Epidemiol 128, 655–666.
28. Pietinen P, Ascherio A, Korhonen P, et al. (1997) Intake of
fatty acids and risk of coronary heart disease in a cohort of
Finnish men: the Alpha-Tocopherol, Beta-Carotene Cancer
Prevention Study. Am J Epidemiol 145, 876–887.
29. Mizrahi A, Knekt P, Montonen J, et al. (2009) Plant foods and
the risk of cerebrovascular diseases: a potential protection of
fruit consumption. Br J Nutr 102, 1075–1083.
30. Pereira MA, O’Reilly E, Augustsson K, et al. (2004) Dietary
fiber and risk of coronary heart disease: a pooled analysis
of cohort studies. Arch Intern Med 164, 370–376.
31. Jakobsen MU, O’Reilly EJ, Heitmann BL, et al. (2009) Major
types of dietary fat and risk of coronary heart disease: a
pooled analysis of 11 cohort studies. Am J Clin Nutr 89,
1425–1432.
32. Albert CM, Oh K, Whang W, et al. (2005) Dietary a-linolenic
acid intake and risk of sudden cardiac death and coronary
heart disease. Circulation 112, 3232–3238.
33. Ascherio A, Rimm EB, Giovannucci EL, et al. (1996) Dietary
fat and risk of coronary heart disease in men: cohort follow
up study in the United States. BMJ 313, 84–90.
34. de Goede J, Verschuren WM, Boer JM, et al. (2011)
a-Linolenic acid intake and 10-year incidence of coronary
heart disease and stroke in 20,000 middle-aged men and
women in the Netherlands. PLOS ONE 6, e17967.
35. Dolecek TA & Granditis G (1991) Dietary polyunsaturated
fatty acids and mortality in the Multiple Risk Factor Interven-
tion Trial (MRFIT). World Rev Nutr Diet 66, 205–216.
36. Oomen CM, Ocke MC, Feskens EJ, et al. (2001) a-Linolenic
acid intake is not beneficially associated with 10-y risk of
coronary artery disease incidence: the Zutphen Elderly
Study. Am J Clin Nutr 74, 457–463.
37. Laaksonen DE, Nyyssonen K, Niskanen L, et al. (2005)
Prediction of cardiovascular mortality in middle-aged men
by dietary and serum linoleic and polyunsaturated fatty
acids. Arch Intern Med 165, 193–199.
38. Lopes C, Aro A, Azevedo A, et al. (2007) Intake and adipose
tissue composition of fatty acids and risk of myocardial
infarction in a male Portuguese community sample. J Am
Diet Assoc 107, 276–286.
39. Campos H, Baylin A & Willett WC (2008) a-Linolenic acid
and risk of nonfatal acute myocardial infarction. Circulation
118, 339–345.
40. Vedtofte MS, Jakobsen MU, Lauritzen L, et al. (2011) Dietary
a-linolenic acid, linoleic acid, and n-3 long-chain PUFA
and risk of ischemic heart disease. Am J Clin Nutr 94,
1097–1103.
a-Linolenic acid and risk of CHD 743
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
